As filed with the U.S. Securities and Exchange Commission on February 29, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
_____________________________________
SENSEI BIOTHERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
_____________________________________
| | |
Delaware | | 83-1863385 |
(State or other jurisdiction of Incorporation or organization) | | (I.R.S. Employer Identification No.) |
1405 Research Blvd, Suite 125
Rockville, MD 20850
(Address of principal executive offices) (Zip code)
_____________________________________
2021 Equity Incentive Plan
2021 Employee Stock Purchase Plan
(Full title of the plan)
_____________________________________
John Celebi
President and Chief Executive Officer
Sensei Biotherapeutics, Inc.
1405 Research Blvd, Suite 125,
Rockville, MD 20850
(240) 243-8000
(Name and address of agent for service) (Telephone number, including area code, of agent for service)
Copies to:
| | |
Mark Ballantyne Michael E. Tenta Cooley LLP 11951 Freedom Drive Reston, VA 20190-5640 (703) 456-8000 | | Christopher W. Gerry General Counsel and Secretary Sensei Biotherapeutics, Inc. 1405 Research Blvd, Suite 125 Rockville, MD 20850 (240) 243-8000 |
_____________________________________
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| |
Large accelerated filer ☐ | Accelerated filer ☐ |
Non-accelerated filer ☒ | Smaller reporting company ☒ |
| Emerging growth company ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
EXPLANATORY NOTE
This Registration Statement on Form S-8 is being filed for the purpose of registering an additional (i) 500,603 shares of Common Stock of Sensei Biotherapeutics, Inc. to be issued pursuant to the 2021 Equity Incentive Plan (“2021 EIP”) and (ii) 250,301 shares of Common Stock of Sensei Biotherapeutics, Inc. to be issued pursuant to the 2021 Employee Stock Purchase Plan (the “2021 ESPP”), pursuant to the provisions of the 2021 EIP
and 2021 ESPP providing for automatic increases in the number of shares of Common Stock reserved and available for issuance under the 2021 EIP and
2021 ESPP on January 1, 2024. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Securities and Exchange
Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.
PART II ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE
The contents of the earlier registration statement relating to (i) the 2018 Stock Incentive Plan, (ii) the 2021 EIP and (iii) the 2021 ESPP, previously filed with the Securities and Exchange Commission on February 10, 2021 (File No. 333-252954) are incorporated herein by reference and made a part
of this Registration Statement.
ITEM 8. EXHIBITS Incorporated by Reference
* Filed herewith.
2.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on this 29th day of February, 2024.
| | | |
| | Sensei Biotherapeutics, Inc. |
| | | |
Date: | February 29, 2024 | By: | /s/ John Celebi |
| | | John Celebi |
| | | President and Chief Executive Officer |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints John Celebi and Erin Colgan, each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in their name, place or stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| | | | |
Name | | Title | | Date |
| | | | |
/s/ John Celebi | | President, Chief Executive Officer and Director (Principal Executive Officer) | | February 29, 2024 |
John Celebi | | | | |
| | | | |
/s/ Erin Colgan | | Chief Financial Officer (Principal Financial and Accounting Officer) | | February 29, 2024 |
Erin Colgan | | | | |
| | | | |
/s/ William Ringo | | Chair | | February 29, 2024 |
William Ringo | | | | |
| | | | |
/s/ Bob Holmen | | Director | | February 29, 2024 |
Bob Holmen | | | | |
| | | | |
/s/ James Peyer, Ph.D. | | Director | | February 29, 2024 |
James Peyer, Ph.D. | | | | |
| | | | |
/s/ Thomas Ricks | | Director | | February 29, 2024 |
Thomas Ricks | | | | |
| | | | |
/s/ Deneen Vojta, M.D. | | Director | | February 29, 2024 |
Deneen Vojta, M.D. | | | | |
| | | | |
/s/ Jessie English, Ph.D. | | Director | | February 29, 2024 |
Jessie English, Ph.D. | | | | |
| | | | |
/s/ Kristian Humer | | Director | | February 29, 2024 |
Kristian Humer | | | | |
| | | | |
3.